×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
03:09 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/18
08:15 am
mbrx
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
Medium
Report
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
11/14
08:18 am
mbrx
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]
High
Report
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]
11/14
08:15 am
mbrx
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
High
Report
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
11/13
03:02 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/13
02:07 am
mbrx
Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]
Medium
Report
Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]
11/12
02:31 pm
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.
11/12
08:00 am
mbrx
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Medium
Report
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
08:21 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 18
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 18
11/18
08:21 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 18
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 18
11/14
05:12 pm
mbrx
Form SC 13G/A Moleculin Biotech, Inc. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SC 13G/A Moleculin Biotech, Inc. Filed by: ARMISTICE CAPITAL, LLC
11/14
08:36 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 14
High
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 14
11/14
08:16 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 14
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 14
11/12
09:36 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 12
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 12
11/12
09:25 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 12
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 12
11/12
09:24 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Nov 11
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Nov 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
TOP News Decliners
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]
-50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: